Economic evaluations of human papillomavirus vaccines
作者： Ruanne V Barnabas , Shalini L Kulasingam
关键词:
摘要: Vaccines to prevent infection with the human papillomavirus (HPV) have recently been approved for use in preventing cervical precancer and cancer. This paper reviews HPV vaccine effectiveness cost–effectiveness studies published date. In order fully appreciate strengths limitations of different studies, a short background is provided on natural history cancer, current prevention strategies trial results Each study then summarized terms model structure, parameter estimates assumptions regarding screening vaccination, key findings. The review concludes recommendations additional research five-year perspective.
expert-reviews.com参考文章(57)
Gillian D. Sanders, Al V. Taira, Cost Effectiveness of a Potential Vaccine for Human papillomavirus Emerging Infectious Diseases. ,vol. 9, pp. 37- 48 ,(2003) , 10.3201/EID0901.020168
D.M Parkin, F.I Bray, S.S Devesa, Cancer burden in the year 2000. The global picture. European Journal of Cancer. ,vol. 37, pp. 4- 66 ,(2001) , 10.1016/S0959-8049(01)00267-2
K M French, R V Barnabas, M Lehtinen, O Kontula, E Pukkala, J Dillner, G P Garnett, Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland British Journal of Cancer. ,vol. 96, pp. 514- 518 ,(2007) , 10.1038/SJ.BJC.6603575
Ralph P Insinga, Erik J Dasbach, Elamin H Elbasha, Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. PharmacoEconomics. ,vol. 23, pp. 1107- 1122 ,(2005) , 10.2165/00019053-200523110-00004
Shalini L. Kulasingam, Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs JAMA. ,vol. 290, pp. 781- 789 ,(2003) , 10.1001/JAMA.290.6.781
Elamin H. Elbasha, Alison P. Galvani, Vaccination against multiple HPV types. Bellman Prize in Mathematical Biosciences. ,vol. 197, pp. 88- 117 ,(2005) , 10.1016/J.MBS.2005.05.004
Jan M. M. Walboomers, Marcel V. Jacobs, M. Michele Manos, F. Xavier Bosch, J. Alain Kummer, Keerti V. Shah, Peter J. F. Snijders, Julian Peto, Chris J. L. M. Meijer, Nubia Mu�oz, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology. ,vol. 189, pp. 12- 19 ,(1999) , 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
Schiffman M Stoler MH, None, Interobserver Reproducibility of Cervical Cytologic and Histologic Interpretations: Realistic Estimates From the ASCUS-LSIL Triage Study JAMA. ,vol. 285, pp. 1500- 1505 ,(2001) , 10.1001/JAMA.285.11.1500
L L Villa, R L R Costa, C A Petta, R P Andrade, J Paavonen, O-E Iversen, S-E Olsson, J Høye, M Steinwall, G Riis-Johannessen, A Andersson-Ellstrom, K Elfgren, G von Krogh, M Lehtinen, C Malm, G M Tamms, K Giacoletti, L Lupinacci, R Railkar, F J Taddeo, J Bryan, M T Esser, H L Sings, A J Saah, E Barr, High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up British Journal of Cancer. ,vol. 95, pp. 1459- 1466 ,(2006) , 10.1038/SJ.BJC.6603469
Constance Mao, Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler, Darron R. Brown, Dorothy J. Wiley, Frances B. Alvarez, Oliver M. Bautista, Kathrin U. Jansen, Eliav Barr, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics & Gynecology. ,vol. 107, pp. 18- 27 ,(2006) , 10.1097/01.AOG.0000192397.41191.FB